GB202312892D0 - Pharmaceutical composition for drug delivery - Google Patents
Pharmaceutical composition for drug deliveryInfo
- Publication number
- GB202312892D0 GB202312892D0 GBGB2312892.9A GB202312892A GB202312892D0 GB 202312892 D0 GB202312892 D0 GB 202312892D0 GB 202312892 A GB202312892 A GB 202312892A GB 202312892 D0 GB202312892 D0 GB 202312892D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- drug delivery
- drug
- delivery
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2312892.9A GB202312892D0 (en) | 2023-08-23 | 2023-08-23 | Pharmaceutical composition for drug delivery |
| PCT/GB2024/052189 WO2025040904A1 (en) | 2023-08-23 | 2024-08-21 | Pharmaceutical composition for drug delivery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2312892.9A GB202312892D0 (en) | 2023-08-23 | 2023-08-23 | Pharmaceutical composition for drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202312892D0 true GB202312892D0 (en) | 2023-10-04 |
Family
ID=88189698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2312892.9A Ceased GB202312892D0 (en) | 2023-08-23 | 2023-08-23 | Pharmaceutical composition for drug delivery |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202312892D0 (en) |
| WO (1) | WO2025040904A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180021259A1 (en) * | 2015-02-10 | 2018-01-25 | Memorial Sloan Kettering Cancer Center | Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use |
| CN108553422A (en) * | 2018-04-28 | 2018-09-21 | 中国科学院上海硅酸盐研究所 | A kind of novel nano drug and preparation method thereof |
-
2023
- 2023-08-23 GB GBGB2312892.9A patent/GB202312892D0/en not_active Ceased
-
2024
- 2024-08-21 WO PCT/GB2024/052189 patent/WO2025040904A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025040904A1 (en) | 2025-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3962455T3 (en) | New pharmaceutical composition for drug delivery | |
| IL289513A (en) | Pharmaceutical composition for nasal delivery | |
| CA215994S (en) | Drug delivery system | |
| CA215995S (en) | Drug delivery system | |
| CA215997S (en) | Drug delivery system | |
| EP4238556A4 (en) | Gastroretentive pharmaceutical dosage form | |
| CA231030S (en) | Drug delivery device | |
| IL317870A (en) | Biopolymer formulations for drug delivery | |
| GB202312892D0 (en) | Pharmaceutical composition for drug delivery | |
| CA233624S (en) | Drug delivery device | |
| GB202507442D0 (en) | Drug delivery device | |
| IL319781A (en) | Oral drug delivery device | |
| EP4096686A4 (en) | Tissue dosing for intraluminal local drug delivery | |
| CA230715S (en) | Drug delivery system | |
| GB202500245D0 (en) | Drug delivery | |
| GB202400865D0 (en) | Drug delivery | |
| EP4096655A4 (en) | Pharmaceutical composition suitable for vaginal delivery | |
| HK40064416A (en) | Pharmaceutical composition for nasal delivery | |
| GB202213744D0 (en) | Drug Delivery Device | |
| CA3280438A1 (en) | Pharmaceutical composition for transnasal administration | |
| GB202301322D0 (en) | Antiemetic pharmaceutical compositions for nasal delivery | |
| HK40113111A (en) | Pharmaceutical composition comprising biopharmaceutical drug compounds | |
| GB202310788D0 (en) | delivery device for medicament | |
| GB202316245D0 (en) | Rapamycin-containing pharmaceutical composition | |
| GB202213668D0 (en) | Improved drug delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |